# Glaukos share price today (Glaukos Corporation, GKOS)

> Glaukos Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GKOS · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/gkos

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $233.04 (+164.6% in a year)
- Revenue (Jun 2026): $186 M (+49.5% on a year ago)
- Profit (Jun 2026): −$18.4 M
- Operating margin: −8.5% (+9.8 points on a year ago)
- ROE: −29%, FY25
- ROIC: −12.5%, against a 7.9% cost of capital: −20.4 points

Biggest thing to watch: the price has already been rising for 23 weeks, so timing is the risk more than the business. ## What is the Glaukos share price today? Glaukos Corporation's share price was $233.04 at the close on 3 November 2026. It has been rising for 23 weeks. That is 63.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $84 and $238, and at that close it sat 97% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 23 weeks in a row. Over the last 10 years the share price moved +697% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Glaukos pay? Glaukos Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Glaukos on? Glaukos is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Glaukos profitable? Glaukos Corporation posted a net loss of $18.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $188 M. That loss is 9.9% of the quarter's revenue. The same quarter a year earlier lost $19.7 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Glaukos make, and is it growing? Glaukos Corporation reported $186 M of revenue in the Jun 2026 quarter, +49.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 14.6% a year on average. The last full year, FY25, came in at $507 M. The last four reported quarters add to $613 M. FY25 revenue was $507 M, +32.3% on the year before. Recent pace: the last four quarters grew +41.1% on average, against 14.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +41.5%, against +33.9% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Glaukos keep? Glaukos Corporation's operating margin was −8.5% in the Jun 2026 quarter, 9.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between −39.3% and −17.1%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +9.8 percentage points on the year while gross margin changed +3.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Glaukos' profit turning into cash? Glaukos Corporation's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $14.8 M of cash, against −$188 M of profit. After $7.7 M of spending on assets, free cash was −$22.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Glaukos' cash go? Glaukos Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $34.2 M on assets over the last 3 years. Averaged over those years that is 2.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $34.2 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Glaukos' P/E ratio, and how does it compare with its own history? Glaukos Corporation has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Glaukos Corporation at 27.2× its FY25 revenue of $507 M. The P/E comes back here once profit turns positive. ## Is the Glaukos business getting better or worse? Glaukos Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Glaukos earn on its capital? Glaukos Corporation earned a ROE of −29% in FY25. Its return on capital used (ROIC) is 20.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −37.0% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −37.0% net margin × 0.57× asset turnover × 1.36× leverage (assets divided by equity) ≈ −28.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −12.5% − 7.9% = −20.4 percentage points. The 7.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −12.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −16.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Glaukos have too much debt? Glaukos Corporation has total debt of $108 M against shareholder equity of $682 M as of Jun 2026, so its debt is 0.16× its equity, which is very little. Year by year, that ratio went from 0.65 in FY21 to 0.16 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Glaukos shareholding pattern? 7.6% of Glaukos Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Glaukos from balance-sheet trouble? For Glaukos Corporation, the Z-score is 16.41. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 16.41 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Glaukos rank in its industry? 57.0 out of 100, rank 7 of 30 in Medical Devices, with 64% of the evidence available. Glaukos Corporation scores 57.0 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 22.2 + 3.9 + 11.2 + 19.7 = 57. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Glaukos compared with? Glaukos ranks 7 of 30 Medical Devices companies on the 4-Factor Sector Score, with 57.0 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · losing its lead · Most evidence points up · 81% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.6/20 · Lead over its industry 2.6% · Lead over S&P 500 8.7% · 1 year 50.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11.6 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · basing · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 3.3/20 · Lead over its industry -15.4% · Lead over S&P 500 -10.3% · 1 year -5.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 3.3 = 63.7 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -5.1%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · quiet · Evidence leans up · 81% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.8/20 · Lead over its industry -38.8% · Lead over S&P 500 -35.7% · 1 year -56.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.8 = 61.7 · What this means: Earnings are strong; relative strength in its sector is -38.8% and the one-year return is -56.5%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.7/20 · Lead over its industry 36.9% · Lead over S&P 500 44.6% · 1 year 76% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.7 = 59.1 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) PODD · turning · Evidence leans up · 71% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -31% · Lead over S&P 500 -27.5% · 1 year -51.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.5 = 58.5 · What this means: Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · basing · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 4.8/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.7% · 1 year -12.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 4.8 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Glaukos Corporation this page GKOS · leader · Evidence leans up · 64% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.7/20 · Lead over its industry 53.6% · Lead over S&P 500 62.8% · 1 year 177.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.7 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Medtronic plc](https://www.sectoralpha.in/us/stocks/mdt) MDT · breaking out · Evidence leans up · 85% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.8/20 · Lead over its industry -1.7% · Lead over S&P 500 3.9% · 1 year 7.2% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · basing · Evidence leans up · 81% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 7.3/20 · Lead over its industry -10.1% · Lead over S&P 500 -4.9% · 1 year -12.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 7.3 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 14.6% · Profit -75.8% · Operating margin change 1.7 points · 83% evidence Capital efficiency 18.6/25 · ROCE 14.8% · Operating margin 29.8% · 76% evidence Valuation 3.9/20 · P/E 51.8× · PEG 5.03 · 65% evidence Relative strength 13.2/20 · Lead over its industry 0.1% · Lead over S&P 500 6.2% · 1 year 14.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.1 + 18.6 + 3.9 + 13.2 = 53.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) PHG · turning · Evidence leans up · 71% evidence 52.3 out of 100 Growth Capital Valuation Relative
12. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · quiet · Evidence leans up · 81% evidence 52.2 out of 100 Growth Capital Valuation Relative
13. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 50.8 out of 100 Growth Capital Valuation Relative
14. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 49.4 out of 100 Growth Capital Valuation Relative
15. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 48.9 out of 100 Growth Capital Valuation Relative
16. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · losing its lead · Evidence leans down · 81% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative
18. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans down · 64% evidence 47.6 out of 100 Growth Capital Valuation Relative
19. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
20. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans down · 81% evidence 45.9 out of 100 Growth Capital Valuation Relative
21. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 44.8 out of 100 Growth Capital Valuation Relative
23. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) BIO · leader · Evidence leans down · 71% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.1 out of 100 Growth Capital Valuation Relative
25. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
26. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.4 out of 100 Growth Capital Valuation Relative
27. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 37.8 out of 100 Growth Capital Valuation Relative
28. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Evidence leans down · 81% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
30. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Glaukos in size? Glaukos is the 11th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Koninklijke Philips N.V., STERIS plc and Zimmer Biomet Holdings, Inc. Just below it: Penumbra, Inc., Smith & Nephew plc and Insulet Corporation. ### Medical Devices companies close in size

1. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) $28.1 billion
2. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) $22.6 billion
3. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) $18.5 billion
4. Glaukos Corporation $13.8 billion
5. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) $12.6 billion
6. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) $12.5 billion
7. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) $10.7 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [AST SpaceMobile, Inc.](https://www.sectoralpha.in/us/stocks/asts) $14.1 billion · Communication Equipment
2. [Toll Brothers, Inc.](https://www.sectoralpha.in/us/stocks/tol) $14.1 billion · Residential Construction
3. Glaukos Corporation $14.1 billion
4. [Regency Centers Corporation](https://www.sectoralpha.in/us/stocks/reg) $14.1 billion · REIT - Retail
5. [Mid-America Apartment Communities, Inc.](https://www.sectoralpha.in/us/stocks/maa) $14.1 billion · REIT - Residential

## What else do people ask about Glaukos? ### What were Glaukos's latest quarterly results? Glaukos Corporation reported revenue of $186 M and a net loss of $18.4 M for the Jun 2026 quarter. Earnings per share were −$0.31. The operating margin was −8.5%, 9.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Glaukos's market cap? Glaukos Corporation's market capitalisation is $13.8 B at a stock price of $233.04. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Glaukos performing? Glaukos Corporation's share price has been rising for 23 weeks. Over the past 13 weeks it has done better than the S&P 500, for 23 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Glaukos's stock price go up? This page does not forecast Glaukos Corporation's stock price. What it shows instead: the stock price is $233.04, and it has been rising for 23 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Glaukos have too much debt? No, Glaukos Corporation has little debt: its debt is 0.15× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Glaukos in its business cycle? Glaukos Corporation's FY25 operating margin was −17.1%, against a 5-year range of −39.3% to −17.1%: the middle of its own range, neither a peak nor a low. The latest quarter was −8.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Glaukos story? Biggest thing to watch: the price has already been rising for 23 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Glaukos a stock worth studying right now? What the numbers show: Glaukos Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.